Solvotrin Therapeuticsbased In Corkirelandis A Healthcare Development Company Founded In 2009It Specializes In Optimizing Established Therapies Through Innovative Formulationsprimarily Under Its Brand Active Ironthe Company Employs A Team Of 11 To 50 People And Has Raised Approximately $10 96 Million In Fundingwith A Significant Round Of $7 79 Million Occurring Four Years Ago Active Iron S Flagship Product Is A Clinically Proven Oral Iron Supplement Designed For Better Absorption And Fewer Gastrointestinal Side Effects Compared To Traditional Iron Therapiesthe Supplement Features A Patented Protein Coated Iron Technology And Targets Demographics Such As Menstruating Individualspregnant Womenand Those Following Plant Based Dietsactive Iron Is Available In 15 Marketsincluding The Usukchinaand Canadawhere It Will Be Launched Under A Partnership With Norwell Consumer Healthcare In 2025The Company Holds Six Patentsincluding One Granted In 2022And Aims To Enhance Global Accessibility In Women S Health And Nutritional Supplementation
